Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Queensland Health
US Department of Justice
Harvard Business School
QuintilesIMS
Cantor Fitzgerald
Federal Trade Commission
Dow
Fish and Richardson

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205085

« Back to Dashboard

NDA 205085 describes CARISOPRODOL, which is a drug marketed by Able, Accelrx Labs, Aurobindo Pharma, Epic Pharma Llc, Hikma Intl Pharms, Ingenus Pharms Nj, Natco Pharma Ltd, Nostrum Labs Inc, Orient Pharma Co Ltd, Oxford Pharms, Pioneer Pharms, Sandoz, Sciegen Pharms Inc, Strides Pharma, Sun Pharm Inds Ltd, Sun Pharm Industries, Vintage Pharms, Watson Labs, Watson Labs Teva, Wilshire Pharms Inc, Heritage Pharms Inc, and Novast Labs Ltd, and is included in thirty-one NDAs. It is available from fifty-four suppliers. Additional details are available on the CARISOPRODOL profile page.

The generic ingredient in CARISOPRODOL is aspirin; carisoprodol; codeine phosphate. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; carisoprodol; codeine phosphate profile page.
Summary for 205085
Tradename:CARISOPRODOL
Applicant:Orient Pharma Co Ltd
Ingredient:carisoprodol
Patents:0
Therapeutic Class:Skeletal Muscle Relaxants
Formulation / Manufacturing:see details
Pharmacology for NDA: 205085
Medical Subject Heading (MeSH) Categories for 205085
Suppliers and Packaging for NDA: 205085
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CARISOPRODOL carisoprodol TABLET;ORAL 205085 ANDA NorthStar RxLLC 16714-510 16714-510-02 500 TABLET in 1 BOTTLE (16714-510-02)
CARISOPRODOL carisoprodol TABLET;ORAL 205085 ANDA NorthStar RxLLC 16714-510 16714-510-03 1000 TABLET in 1 BOTTLE (16714-510-03)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength350MG
Approval Date:Oct 28, 2014TE:AARLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Express Scripts
Deloitte
Boehringer Ingelheim
Daiichi Sankyo
Johnson and Johnson
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot